Effect of mandatory interim reporting frequency on the cost of capital around the world

Thirty years after water privatization—is the English model the envy of the world?

Oxford Review of Economic Policy ◽

10.1093/oxrep/grz031 ◽

2020 ◽

Vol 36 (1) ◽

pp. 69-85 ◽

Cited By ~ 2

Author(s):

Dieter Helm

Keyword(s):

Cost Of Capital ◽

Superior Performance ◽

Water Regulation ◽

Water Privatization ◽

Balance Sheets ◽

The World ◽

Private Incentives ◽

Regulation Model ◽

The Cost

Abstract The paper considers whether water privatization 30 years ago has delivered the promised superior performance to nationalization, which remains the dominant model in Europe. The paper sets out the arguments at privatization, in particular in relation to efficiency, the managerial incentives, the role of private-sector balance sheets in facilitating investment, and the impacts on the cost of capital. Alternative explanations of relative performance, notably the regulation model adopted, are highlighted, and the paper concludes by outlining an alternative model of water regulation which better marries up public responsibilities and private incentives.

Download Full-text

Using Discounted Cash Flow Analysis in an International Setting: A Survey of Issues in Modeling the Cost of Capital

CFA Digest ◽

10.2469/dig.v29.n3.532 ◽

1999 ◽

Vol 29 (3) ◽

pp. 75-77

Author(s):

Joseph Vu

Keyword(s):

Cash Flow ◽

Cost Of Capital ◽

Flow Analysis ◽

Discounted Cash Flow ◽

International Setting ◽

The Cost

Download Full-text

Glembotskaya G.T., Eremin S.Yu. Scientific and practical approach to optimizing costs on development and promotion of drugs

Vestnik Roszdravnadzora ◽

10.35576/article_5d135f4a416e79.00661162 ◽

2019 ◽

Vol 2019 (3) ◽

pp. 47-53

Author(s):

Галина Глембоцкая ◽

Galina Glembockaya ◽

Станислав Еремин ◽

Stanislav Eremin

Keyword(s):

Scientific Literature ◽

Pharmacological Action ◽

Pharmaceutical Market ◽

Pharmaceutical Companies ◽

Strategic Development ◽

The World ◽

The Russian Federation ◽

The Cost ◽

Further Development ◽

Registration Phase

In order to identify promising strategic development possibilities for the pharmaceutical industry in the Russian Federation, a pilot study was conducted, which has analyzed the main trends in the development of innovative medicines. As a result of the content analysis of available sources of scientific literature, the characteristics of options used in the world practice for increasing the innovative activity of individual subjects and the pharmaceutical market as a whole are presented. Possible reserves for the further development of the innovative component of the pharmaceutical market within the framework of the concept of personalized medicine according to the P4 principle (predictive - personalized - preventive - participatory) are identified and structured. The results of use by individual pharmaceutical companies of scientifically and practically justified approaches to optimizing the costs of development and promoting drugs are presented. The advantages and real prospects of a generally accepted method to reduce the cost of development by «expanding the pharmacological effect» (label expansion) of already existing drugs with a known safety profile in the world practice are shown. A scientific generalization and structuring of the goals and results of the post-registration phase of clinical trials to expand the pharmacological action of a number of drugs already existed at the market have been carried out.

Download Full-text